Dendritic cells: Development, function and potential use for cancer immunotherapy

Blood Reviews

Volumn 13, Issue 1, 1999, Pages 51-64

  Avigan, D ^a  

^a Israel Deaconess Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CLONAL ANERGY; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; MONOCYTE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE;

EID: 0032917835     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(99)90023-1     Document Type: Article

References (123)

1. Steinman RM. The dendritic system and its role in immunogenicity. Ann Rev Immunol 1991; 9: 271 296.
2. Germain RN. The biochemistry and cell biology of antigen presentation by MHC Class I and Class II molecules: Implications for the development of combination vaccines. Ann NY Acad Sci 1995; 754: 114.
3. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28 mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992; 356: 607-609.
4. Young JW, Kouliva L, Soergel SA, Clark EA, Steinman RM, Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin invest 1992; 90: 229-237.
5. Boon T, Van der Bruggcn P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
6. Carrel S, Johnson JP. Immunologic recognition of malignant melanoma by autologous T lymphocytes. Curr Opin Oncol 1993; 5: 383-389.
7. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
8. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associates with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
9. Speiser DE, Miranda R, Zakarian A, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells. J Exp Med 1997 186:645
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142-1162.
11. Young JW, Steinman RM. The hematopoietic development of dendritic cells. A distinct pathway for myeloid differentiation. Stem Cells 1996; 14: 376-387.
12. Zhou L-J, Tedder TF. Human blood dendritic cells selectively express CD83: A member of the immunoglobulin super family. J Immunol 1995; 154: 3821- 3835.
13. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978; 75(10): 5132-5136.
14. Van Voorhis WC, Valinsky J, Hoffman E, Luban J, Hair LS, Steinman RM. Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 1983; 158(1): 174-191.
15. Cassell DJ, Schwartz RH. A quantitative analysis of antigen presenting cell function: Activated B cells stimulate naive CD4 T cells but are inferior to DC in providing costimulation. J Exp Med 1994; 180(5): 1829-1840.
16. Ellis J, Chain BM, Davies DH et al. Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL)-2, 1L-4 and interferon gamma by allogeneic T cells Eur J Immunol 1991; 21(11): 2803-2809.
17. Bhardwaj N, Friedman SM, Cole BC, Nisanian AJ. Dendritic cells are potent antigen presenting cells for microbial superantigens. J Exp Med 1992; 175(1): 267-273.
18. Inaba K, Young JW, Steinman RM. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987; 166(1): 182-194.
19. Inaba K, Steinman RM. Protein specific helper T-lymphocyte formation initiated by dendritic cells. Science 1985 229(4712): 475-479.
20. Fayette J, Dubois B, Vandenabeele S et al. Human dendritic cells skew isotype switching of CD40 activated naive B cells towards IgA1 and IgA2. J Exp Med 1997; 185: 1909-1918.
21. Inaba K. Witmer-Pack M, Inaba M et al. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994; 180: 1849-1860.
22. Caux C, Vanbervliet B, Massacrier C et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180(5): 1841-1847.
23. Gapin L, Bravo de Alba Y, Casrouge A, Cabaniols JP, Kourilsky P, Kanellopoulos J. Antigen presentation by dendritic cells focuses T cell responses against immunodominant peptides: Studies in the hen egg-white lysozyme model. J immunol 1998; 160(4): 1555-64.
24. Inaba K., Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Geurin organisms and sensitize mice to mycobacterial antigens in vivo. J Exp Med 1993; 178(2): 479-488.
25. Celluzzi CM, Falo, Jr. LD. Epidermal dendritic cells induce potent antigen specific CTL mediated immunity. J Invest Dermatol 1997; 108(5): 716-720.
26. Inaba K, Metaly JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen specific: MHC restricted T cells in situ. J Exp Med 1990; 172: 631-640.
27. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with tumor associated antigen gene. Cancer Res 1996; 56(24): 5672-5677.
28. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186(7): 1177-1182.
29. Svensson M, Stockinger B, Wick MJ. Bone marrow derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol 1997; 158(9): 4229-4236.
30. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation of dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989; 169: 1255-1264.
31. Bhardwaj N. Bender A, Gonzalez N, Bui LK, Garret MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest 1994; 94: 797-807.
32. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas Ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158(12): 5676-5684.
33. Steinman RM, Inaba K. The binding of antigen presenting cells to T lymphocytes. Adv Exp Med Biol 1988; 237: 31-41.
34. Jonuleit H, Weidmann K, Muller G et al. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: A role for IL-15 in attraction of T cells. J Immunol 1997; 158(6): 2610-2615.
35. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells. J Exp Med 1987: 165(2): 515-530.
36. Characteristics of antigen-independent and antigen-dependent interaction of dendritic cells with CD4+ T cells. Eur J Immunol 1995; 25(8): 2285-2294.
37. Scheere RA, Koopman G, Van der Baan S. Meijer CJ, Pals ST. Adhesion receptors involved in clustering of blood dendritic cells and T lymphocytes. Eur J Immunol 1992; 21(5): 1101-1105.
38. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180(4): 1263-1272.
39. McLellan AD, Sorg RV, Williams LA, Hart DN. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand dependent pathway. Eur J Immunol 1996; 26(6): 1204-1210.
40. Kelsall BL, Stuber E, Neurath M, Strober W. Interleukin 12 production by dendritic cells: The role of CD40-CD40L interactions in Th1 T cell responses. Ann NY Acad Sci 1996; 795: 116-126.
41. Cella M, Scheidegger D, Palmer-Lehman K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin 12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184(2): 747 752.
42. Macatonia SE, Hosken NA, Litton M et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+T cells. J Immunol 1996; 156(4): 1402-1407.
43. Grohmann U, Bianchi R, Ayroldi E et al. A tumor associated and self antigen peptide present by dendritic cells may induce T cell anergy in vivo but IL-12 can prevent or revert the anergic state. J Immunol 1997; 158(8): 3593-3602.
44. Bhardwaj N, Seder RA, Reddy A, Feldman MV. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest 1996; 98(3): 715-722.
45. Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci 1996; 795: 284-293.
46. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavailon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158(6): 2919-2925.
47. Koch F, Stanzl U, Jennewein Pet al. High level IL-12 production by murine dendritic cells. J Exp Med 1996; 184(2): 741-746.
48. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10 treated dendritic cells. J Immunol 1997; 159(10): 4772-4780.
49. Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28(1): 359-369.
50. Morel AS, Quarantino S, Douek DC Londei M. Split activity of interleukin 10 on antigen capture and antigen presentation by human dendritic cells. Eur J Immunol 1997; 27(1): 26-34.
51. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin 10 prevents dendritic cell accumulation and vaccination with GM-CSF gene modified tumor cells. J Immunol 1997; 159(2): 770-776.
52. Sertl K, Takemura T, Tschachler E, Ferrans VJ, Kaliner MA, Shavach EM. Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma and visceral pleura. J Exp Med 1986; 163(2): 436-451.
53. Katz SL, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282: 323-326.
54. Strunk D, Egger C, Leitner G, Hanau D, Stingl G. A skin homing define the Langcrhans cell progenitor in human peripheral blood. J Exp Med 1997; 186(6): 1131 1136.
55. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996; 183: 1287-1292.
56. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med 1995; 182: 283-288.
57. Kampgen E, Koch N, Koch F et al. Class II major histocompatibility complex molecules of murine dendritic cells. Proc Natl Acad Sci USA 1991; 88(8): 3014-3018.
58. Shcn Z, Reznikoff G, Dranoff, G, Rock, KL. Cloned dendritic cells can present exogenous antigens on both MHC Class I and Class II molecules. J Immunol 1997; 158(6): 2723 2730.
59. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apopototic cells and induce Class I restricted CTL. Nature 1998; 392(6671): 86-89.
60. Jiang W, Swiggard WJ, Heufler C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995: 275(6527): 151 155.
61. Tan MC, Mommaas AM, Drijfhout JW et al. Mannose receptor mediated uptake of antigens strongly enhances HLA Class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 1997; 27(9): 2426 2435.
62. Nijnian HW, Leijmeer MJ, Ossevoort MA et al. Antigen capture and major histocompatibility Class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med 1995; 182(1): 163-174.
63. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161(3): 526-546.
64. Romani N, Koide S, Crowley M et. al. Presentation of exogenous protein antigens by dendritic cells to T cell clones: Intact protein is presented best by immature epidermal Langerhans cells. J Exp Med 1989; 169: 1169 1178.
65. Watts C. Inside the gearbox of the dendritic cell. Nature 1997; 388: 724 725.
66. Witmer-Pack MD, Olivier W, Valinsky J. GM-CSF is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987; 166: 1484-1498.
67. Kampgen E, Koch F, Heufler C. Understanding the dendritic cell lineage through a study of cytokine receptors. J Exp Med. 1994; 179: 1767 1776.
68. Markowitz S, Engelman EG. GM-CSF promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990; 85: 955-961.
69. Santiago-Schwartz F, Divaris N, Kay C, Carsons SE. Mechanisms of tumor necrosis factor-granulocyte macrophage colony stimulating factor induced dendritic cell development. Blood 1993; 82(10): 3019 3028.
70. Flores-Romo L, Bjorck P, Duvert V, van Kooten C, Saeland S, Vanchereau J. CD40 I ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J Exp Med 1997; 185(2): 341 349.
71. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J Exp Med 1992; 176: 1693-1702.
72. Young JW, Szabolcs P, Moore MAS. Identification of dendritic cell colony forming units among normal CD34+ bone marrow progenitors that are expanded in c-kit ligand and yield pure dendritic cell colonies in the presence of GM-CSF and TNFα. J Exp Med 1995; 182: 1111-1120.
73. Saraya K, Reid CD. Stem cell factor and the regulation of dendritic cell production from CD34+ progenitors in bone marrow and cord blood. Br J Haematol 1996; 93(2): 258 264.
74. Rosenzweig M, Canquc B Gluckman JC. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 1996; 87: 535 544.
75. Caux C, Vanbervliet B, Massacricr C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF and TNFα. 1996; J Exp Med 184: 695-706.
76. Szabolcs P, Avigan D, Gezelter S, Ciocon DH, Moore MAS, Steinman RM, Young JW. Denritic cells and macrophages can mature independently from human bone marrow-derived post colony forming unit intermediate. Blood 1996; 87: 4520-4530.
77. O'Doherty U, Steinman RM, Peng M et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte conditioned medium. J Exp Med 1993; 178(3): 1067-1076.
78. O'Doherty U, Pneg M, Gezelter S et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82(3): 487-493.
79. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen presenting cells. J of Immunol 1994; 153: 4016-4028.
80. Zhou L, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
81. Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNFα. J Immunol 1995; 154: 5851 5861.
82. Bernhard H, Disis ML, Heinfeld S, Hand S, Gralow JR, Cheever MA. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995; 55: 1099-1104.
83. Caux C, Dezutter-Dambuyant C. Schmitt D, Banchereau J. GM-CSF and TNFα cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
84. Shurin MR, Pandharipande PP. Zorina TD et al. Flt3 Ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997; 179(2): 174 184.
85. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83 93.
86. Tarte K, Lu ZY, Fiol G, Legouffe E, Rossi JF, Klein B. Generation of virtually pure and potentially proliferating dendritic cells from patients with multiple myeloma. Blood 1997; 90: 3482-3485.
87. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179: 1109-1118.
88. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196(2): 121-135.
89. Mehta-Damani A, Markowitz S, Engleman E. Generation of antigen specific CD8+ CTLs from naive precursors. J Immunol 1994; 153 (3): 996 1003.
90. Porgador A, Giboa E. Bone marrow generated dendritic cells pulsed with Class 1-restricted peptide are potent inducers for cylotoxic T lymphocytes. J Exp Med 1995; 182(1): 255 260.
91. Aicher A, Westerman J, Cayeux S et al. Successful retroviral mediated transduction of a reporter gene in human dendritic cells. Exp Hematol 1997; 25(1): 39 44.
92. Song ES, Lee V, Surh CD et al. Antigen presentation in retroviral vector mediated gene transfer in vivo. Proc Natl Acad Sci USA 1997; 94(5): 1943-1948.
93. Alijagic S. Moller P, Artuc M, Jurgovsky K, Czamelzki BM, Schadendorf D. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 1995: 25(11): 3100-3107.
94. Arthur JF, Butterfield LH, Roth MD et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4(1): 17-25.
95. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding major histocompatibility complex Class II-restricted viral epitope. J Exp Med 1997; 186(9): 1481-1486.
96. Esche C, Subbotin VM, Maliszeksi C, Lotze MT, Shurin MR. Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998; 58(3): 380-383.
97. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997; 3(6): 625-631.
98. Celluzzi CM, Mayordomo C, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287.
99. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 1: 1297-302.
100. Debruijn ML, Schuurhuis DH, Veirboom MP et al. Immunization with human papillomavirus type 16 oncoprotien loaded dendritic cells as well as protein as adjuvant induces NHC Class I-restricted portection to HPV 1-16 induced tumor cells. Cancer Res 1998; 58(4): 724-731.
101. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 184(4); 1357-1365.
102. Bakker AB, Marland G, de Boer AJ et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995; 55(22): 5330-5334.
103. Peiper M, Goedegebuure PS, Eberlein TJ. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells. Surgery 1997; 122(2): 235 241; discussion 241-242.
104. Alters SE, Gadea JR, Sorich M, O'Donoghue G, Talib S, Philip R. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 1998; 21(1): 17-26.
105. Mannering SI, McKenzie JL, Fearnley DB, Hart DN. HLA-DR 1-restricted bcr-ab1 (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997; 90(1): 290-297.
106. Nieda M, Nicol A, Kikuchi A et al. Dendritic cells stimulate the expansion of bcr-ab1 specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91(3): 977-983.
107. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317-322.
108. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induced tumor resistance in vivo. Eur J Immunol 1994; 24(3): 605-610.
109. Ribas A, Butterfield LH, McBride WH et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997; 57(14): 2865-2869.
110. Song W, Kong HL, Carpenter H et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186(8): 1247-1256.
111. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996; S6(16): 3763-3770.
112. Specht JM, Wang G, Do MT et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186(8): 1213-1221.
113. Boczkowski D, Nair Sk, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2): 465-472.
114. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27(10): 2702-2707.
115. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2(10): 1122-1128.
116. Zitovogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumors peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183(1): 87-97.
117. DeMatos P, Abdel-Wakab Z, Vervaert C, Hester D, Seigel H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yield equally effective vaccine against B16 tumours in mice. Surg Oncol 1998; 68(2): 79-91.
118. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186(7): 1177-1182.
119. Gong JL, Chen D, Chen D et al. Induction of antigen specific antitumor immunity with adenoviral transduced dendritic cells. Gene Therapy 1997; 4: 1023.
120. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2(1): 52 58.
121. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3): 328-332.
122. Caux P, Favre N, Martin M. Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72(4): 619-624.
123. Siena S, Di Nicola M, Bregni M et al. Massive ex vivo generation of function dendritic cells from mobilized CD34+ blood progenitors fro anticancer therapy. Exp Hematol 1995; 23: 1463-1471.